Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vertex Pharmaceuticals
(NQ:
VRTX
)
445.21
+4.57 (+1.04%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vertex Pharmaceuticals
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
42
43
Next >
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future.
Via
InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
July 07, 2022
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say.
Via
Investor's Business Daily
Why Top-Notch Biotech Stock Vertex Pharmaceuticals Just Hit A Record
July 06, 2022
The stock hit its highest point in decades Wednesday on key FDA action.
Via
Investor's Business Daily
FDA Lifts Clinical Hold On Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial
July 05, 2022
Via
Benzinga
Analyzing Vertex Pharmaceuticals's Short Interest
July 05, 2022
Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has fallen 11.26% since its last report. The company recently reported that it has 3.42 million shares sold short,...
Via
Benzinga
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
July 05, 2022
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91.
Via
Investor's Business Daily
FDA Lifts Clinical Hold On Vertex's Initial-Stage Diabetes Study
July 05, 2022
The U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on Vertex Pharmaceuticals’ (NASDAQ: VRTX) Phase 1/2 clinical trial of VX-880 for patients with type 1 diabetes (T1D).
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
July 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96
June 30, 2022
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before.
Via
Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
June 30, 2022
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier.
Via
Investor's Business Daily
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
June 30, 2022
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.
Via
Investor's Business Daily
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
June 28, 2022
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before.
Via
Investor's Business Daily
Why Jim Cramer Prefers Devon Energy Over EOG Resources
June 23, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Devon Energy Corporation (NYSE: DVN) over EOG Resources, Inc. (NYSE: EOG) as the former is cheaper.
Via
Benzinga
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
June 23, 2022
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year.
Via
Investor's Business Daily
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
June 22, 2022
With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in.
Via
InvestorPlace
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
June 17, 2022
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals...
Via
Benzinga
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
June 15, 2022
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92.
Via
Investor's Business Daily
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
June 13, 2022
Crispr and Vertex tested their gene-edited drug in two blood diseases.
Via
Investor's Business Daily
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
June 13, 2022
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic...
Via
Benzinga
Expert Ratings for Vertex Pharmaceuticals
June 13, 2022
Over the past 3 months, 8 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
June 10, 2022
The company is using a different approach to tackle the blood disease.
Via
Investor's Business Daily
7 of the Hottest ETFs to Buy Right Now
June 09, 2022
These are the hottest ETFs to buy in June whether you're looking for discounts or ETFs that are already on the move.
Via
InvestorPlace
Pacira Pharmaceuticals Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
June 08, 2022
On Wednesday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 66 to 75.
Via
Investor's Business Daily
Regeneron Pharmaceutical Stock Sees RS Rating Jump To 82
June 08, 2022
Looking for the best stocks to buy? Focus on those with rising relative price strength, such as Regeneron Pharmaceutical stock.
Via
Investor's Business Daily
Vertex Pharma Gains FDA Breakthrough Therapy Designation For Kidney Disease Drug
June 08, 2022
Vertex Pharmaceuticals (NASDAQ: VRTX) received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate inaxaplin (VX-147) for the treatment of patients...
Via
Benzinga
7 Oversold Stocks to Buy Right Now
June 08, 2022
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price.
Via
InvestorPlace
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
June 03, 2022
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 4.83% on an annualized basis producing an average annual return of 16.83%. Currently, Vertex Pharmaceuticals...
Via
Benzinga
IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize
June 01, 2022
One analyst expects multiple new drug launches between 2024-26.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022
June 01, 2022
Upgrades
Via
Benzinga
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.